Increased cefepime MIC for enterobacteriacae clinical isolates

Authors

  • Arman Shoujaiifar
  • Farhang Babamahmoudi
  • Roya Ghasemiyan
  • Ahmad Alikhani
  • AliReza Davoudi
  • Narges Najafi
  • Shahriar Aliyan
Abstract:

Background: Cefepime was used as empirical treatment in ventilator-associated pneumonia (VAP) induced by gram-negative and gram-positive bacteria. This study aimed to determine the antimicrobial susceptibility pattern of cefepime against microorganism causing VAP in Mazandaran, North of Iran. Methods: This study was performed on VAP patients diagnosed with clinical pulmonary infection score (CPIS) scores in ICU of two hospitals. For each patient suspected of having VAP, quantitative culture of endotracheal aspiration (QEA) was performed and MIC was determined by micro dilution test. Data were collected and analyzed.Results: Thirty- five cases of enterobacteriaceae were isolated orderly including E coli 13, P. aeruginosa 11, Enterobacter 7 and K. pneumonia 4 cases. All the isolated E. coli, Enterobacter and Klebsiella, 54.5% of P. aeruginosa isolated were fully resistant to cefepime. Conclusion: The results of this study show that cefepime is not a reasonable choice for empirical treatment of nosocomial pneumonia and VAP.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Increased cefepime MIC for enterobacteriacae clinical isolates.

UNLABELLED Background : Cefepime was used as empirical treatment in ventilator-associated pneumonia (VAP) induced by gram-negative and gram-positive bacteria. This study aimed to determine the antimicrobial susceptibility pattern of cefepime against microorganism causing VAP in Mazandaran, North of Iran. METHODS This study was performed on VAP patients diagnosed with clinical pulmonary infect...

full text

increased cefepime mic for enterobacteriacae clinical isolates

background: cefepime was used as empirical treatment in ventilator-associated pneumonia (vap) induced by gram-negative and gram-positive bacteria. this study aimed to determine the antimicrobial susceptibility pattern of cefepime against microorganism causing vap in mazandaran, north of iran. methods: this study was performed on vap patients diagnosed with clinical pulmonary infection score (cp...

full text

Cefepime MIC breakpoint resettlement in gram-negative bacteria.

Cefepime has recently drawn much attention, due mostly to a meta-analysis reported by Yahav et al. (3). They observed higher all-cause mortality for cefepime than for other betalactam antibiotics (risk ratio, 1.26; 95% confidence interval [CI], 1.08 to 1.49) and described neurotoxic adverse effects and inadequate in vivo antimicrobial efficacy as plausible reasons for increased mortality. Bhat ...

full text

Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

BACKGROUND Extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae isolates are important clinical pathogens. In addition, the efficacy of cefepime for such infections is controversial. METHODS We performed a retrospective study of monomicrobial bacteremia caused by ESBL producers at 2 medical centers between May 2002 and August 2007. The patients definitively treated with in vitro ...

full text

Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.

The class C beta-lactamase from Enterobacter cloacae P99 confers resistance to a wide range of broad-spectrum beta-lactams but not to the newer cephalosporin cefepime. Using PCR mutagenesis of the E. cloacae P99 ampC gene, we obtained a Leu-293-Pro mutant of the P99 beta-lactamase conferring a higher MIC of cefepime (MIC, 8 microg/ml, compared with 0.5 microg/ml conferred by the wild-type enzym...

full text

Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapy

Methicillin-resistant S. aureus (MRSA) has emerged as the most common hospital-acquired pathogen and is associated with increased morbidity and mortality compared with other strains. Vancomycin has been the cornerstone of treatment of patients with serious MRSA infections for some decades and while more than 99% of clinical S. aureus isolates remain susceptible to vancomycin, we are beginning t...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue None

pages  654- 657

publication date 2013-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023